Hoy en día, más del 40 por ciento de la población mundial está en riesgo de contraer el dengue y el dengue grave
Informe
Ciudad de México, México - mayo 23 y 24, 2014
Ciudad de México, México - 26 al 28 de mayo del 2014
Este documento muestra las acciones que son requeridas para la prevención, control, vigilancia y coordinación multisectorial para una adecuada y efectiva acción frente al riesgo sanitario que implica la introducción del CHIKV en nuestro país
The Handbook on Law and Disaster Risk Reduction (the Handbook) has been developed to provide guidance on how to use the Checklist and conduct related legislative reviews and reform processes. While the methodology for using the Checklist needs to be tailored to each country’s context and respectiv...e needs, the Handbook is intended to provide general guidance on key steps to consider.
more
WHO Zika Virus Fact Sheet (Portuguese)
Updated: January 2016
WHO Fact sheet on Zika virus (Spanish)
Updated: January 2016
El propósito de este documento es brindar a los profesionales de salud que asisten a mujeres gestantes, información actualizada en base a las mejores evidencias disponibles para prevenir la infección, diagnosticarla oportunamente, sugerir tratamiento, dar seguimiento a las embarazadas, así c...omo notificar el caso a las autoridades sanitarias competentes.
more
WHO Factsheet (Portuguese version). January 2016
Informe
Bogotá, 13-14 de abril del 2015
Mem Inst Oswaldo Cruz , Rio de Janeiro, Vol. 110 (3): 377-386, May 2015
· Relevant interventions
· HIV country profiles
· Adolescents country profiles
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more
Preferential option for the poor in the South African
context of poverty
Missionalia 43:3 (349–364)